〈聯亞新冠疫苗〉未通過緊急使用授權 向TFDA提訴願 | Anue鉅亨 - 台股新聞
聯亞藥 (6562-TE) 母公司聯亞生技開發的新冠疫苗 UB-612 未通過專案製造甚查 (緊急使用授權 EUA)，今 (4) 日代母公司公告，將把審查結果向台灣衛福部食藥署 (TFDA) 提出訴願。
林政勳 mark this message contains misinformation
｜originally written by 林政勳
聯亞新冠疫苗〉未通過緊急使用授權 向TFDA提訴願流程進行中
References
https://www.google.com/amp/s/amp-news.cnyes.com/news/id/4734466https://www.google.com/amp/s/amp-news.cnyes.com/news/id/4734466
The content above by Cofacts message reporting chatbot and crowd-sourced fact-checking community is licensed under Creative Commons Attribution-ShareAlike 4.0 (CC BY-SA 4.0), the community name and the provenance link for each item shall be fully cited for further reproduction or redistribution.